AB
ABT.US Abbott Laboratories
- Market cap
- USD 186B
- P/E
- 40.0x
- P/B
- 3.71x
- ROE
- 7.6%
- Dividend yield
- 2.22%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ABT.US undervalued?
Graham numberABT.US trades 156.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abbott Laboratories fundamental analysis
No fundamental analysis for Abbott Laboratories yet.
Abbott Laboratories stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hor…
Full company profileAbbott Laboratories financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Abbott Laboratories annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 20.9B | 27.4B | 30.6B | 31.9B | 34.6B | 43.1B | 43.7B | 40.1B | 42.0B | 44.3B | 49.0B |
| Gross Profit | 11.2B | 13.1B | 15.8B | 16.7B | 17.4B | 23.2B | 22.3B | 20.0B | 21.3B | 24.6B | 28.0B |
| Operating Income | 3.25B | 1.97B | 3.84B | 4.59B | 5.29B | 9.20B | 8.36B | 6.44B | 6.83B | 8.05B | 6.64B |
| EBITDA | 3.07B | 6.13B | 6.88B | 7.91B | 9.00B | 12.2B | 11.9B | 10.6B | 10.8B | 11.9B | 10.5B |
| Net Income | 1.40B | 477M | 2.37B | 3.69B | 4.50B | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B | 3.90B |
| EPS | 0.94 | 0.27 | 1.34 | 2.07 | 2.52 | 3.95 | 3.93 | 3.27 | 7.67 | 3.73 | 2.24 |
| Balance Sheet | |||||||||||
| Total Assets | 55.0B | 76.3B | 67.2B | 67.9B | 72.5B | 75.2B | 74.4B | 73.2B | 81.4B | 86.7B | 108B |
| Total Liabilities | 31.9B | 45.2B | 36.5B | 36.6B | 39.5B | 39.2B | 37.5B | 34.4B | 33.5B | 33.9B | 56.6B |
| Shareholders' Equity | 20.5B | 30.9B | 30.5B | 31.1B | 32.8B | 35.8B | 36.7B | 38.6B | 47.7B | 52.1B | 51.0B |
| Cash & Short-term Investments | 18.8B | 9.61B | 4.09B | 4.14B | 7.15B | 10.2B | 10.2B | 7.28B | 7.97B | 8.94B | 4.30B |
| Total Debt | 22.0B | 27.9B | 19.6B | 19.1B | 19.9B | 19.3B | 17.9B | 15.9B | 15.3B | 15.1B | 31.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.20B | 5.57B | 6.30B | 6.14B | 7.90B | 10.5B | 9.58B | 7.26B | 8.56B | 9.57B | 7.39B |
| Capital Expenditure | 1.12B | 1.14B | 1.39B | 1.64B | 2.18B | 1.89B | 1.78B | 2.20B | 2.21B | 2.17B | 1.88B |
| Free Cash Flow | 2.08B | 4.44B | 4.91B | 4.50B | 5.72B | 8.65B | 7.80B | 5.06B | 6.35B | 7.40B | 5.51B |
| Ratios | |||||||||||
| ROE | 6.8% | 1.5% | 7.8% | 11.9% | 13.7% | 19.8% | 18.9% | 14.8% | 28.1% | 12.5% | 7.6% |
| ROA | 2.5% | 0.6% | 3.5% | 5.4% | 6.2% | 9.4% | 9.3% | 7.8% | 16.5% | 7.5% | 3.6% |
| Net Profit Margin | 6.7% | 1.7% | 7.7% | 11.6% | 13.0% | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% | 8.0% |
| Debt to Equity | 1.07x | 0.90x | 0.64x | 0.61x | 0.61x | 0.54x | 0.49x | 0.41x | 0.32x | 0.29x | 0.61x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Abbott Laboratories dividends
- Dividend yield
- 2.22%
- Forward dividend
- 2.52 USD
- Payout ratio
- 63.1%
- Ex-dividend date
- Oct 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 4.12B | 2.36 | 63.1% |
| 2024 | USD 3.84B | 2.19 | 28.6% |
| 2023 | USD 3.56B | 2.03 | 62.1% |
| 2022 | USD 3.31B | 1.88 | 47.7% |
| 2021 | USD 3.20B | 1.79 | 45.3% |
| 2020 | USD 2.56B | 1.43 | 57.0% |
| 2019 | USD 2.27B | 1.27 | 61.6% |
| 2018 | USD 1.97B | 1.12 | 83.4% |
| 2017 | USD 1.85B | 1.06 | 387.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10000:4798 on Jan 2, 2013.
Who owns Abbott Laboratories
- Insiders 0.49%
- Institutions 82.57%
- Public & others 16.94%
- Shares outstanding 1.73B
- Free float 1.72B
Top funds holding ABT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 54.9M | 3.17% | -0.78% | Sep 2026 |
| Vanguard 500 Index Investor | 45.4M | 2.62% | -1.80% | Sep 2026 |
| Schwab US Dividend Equity ETF™ | 42.5M | 2.46% | +0.09% | Oct 2026 |
| iShares Core S&P 500 ETF | 23.1M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 22.5M | 1.30% | -0.54% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 21.1M | 1.22% | -0.25% | Oct 2026 |
| American Funds Washington Mutual A | 17.5M | 1.01% | -2.05% | Sep 2026 |
| Vanguard MStar Value Index Investor | 16.5M | 0.95% | -1.01% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 12.7M | 0.73% | +0.88% | Oct 2026 |
| American Funds Invmt Co of Amer A | 11.0M | 0.63% | +6.21% | Sep 2026 |
| American Funds American Mutual A | 10.0M | 0.58% | +59.39% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 9.79M | 0.57% | -0.71% | Sep 2026 |
| Vanguard Institutional Index I | 9.15M | 0.53% | -1.70% | Sep 2026 |
| American Funds Capital Inc Bldr A | 8.54M | 0.49% | +45.59% | Sep 2026 |
| MFS Value A | 7.67M | 0.44% | -2.89% | Sep 2026 |
| Vanguard High Dividend Yield ETF | 7.05M | 0.41% | +0.28% | Sep 2026 |
| JPMorgan Equity Income I | 6.26M | 0.36% | 0.00% | Sep 2026 |
| iShares US Medical Devices ETF | 6.13M | 0.35% | -1.12% | Oct 2026 |
| American Funds Cptl Wld Gr&Inc A | 5.57M | 0.32% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 5.32M | 0.31% | +0.13% | Sep 2026 |
Top institutions holding ABT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 153M | 8.81% | +4.72% | Jun 2026 |
| Vanguard Capital Management, LLC | 114M | 6.57% | +0.71% | Jun 2026 |
| State Street Corp | 80.9M | 4.67% | +1.70% | Jun 2026 |
| Charles Schwab Investment Management Inc | 59.7M | 3.45% | +31.15% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 49.0M | 2.83% | +2.24% | Jun 2026 |
| Geode Capital Management, LLC | 39.2M | 2.26% | +0.18% | Jun 2026 |
| Capital Research Global Investors | 36.9M | 2.13% | -25.85% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 34.7M | 2.00% | -7.58% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 26.6M | 1.54% | -11.60% | Jun 2026 |
| NORGES BANK | 23.4M | 1.35% | -0.43% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 22.8M | 1.32% | +31.89% | Jun 2026 |
| Franklin Templeton Inc | 18.8M | 1.09% | -6.07% | Jun 2026 |
| Northern Trust Corp | 18.3M | 1.06% | -5.78% | Jun 2026 |
| Bank of America Corp | 17.7M | 1.02% | -8.34% | Jun 2026 |
| The Goldman Sachs Group Inc | 16.8M | 0.97% | +15.55% | Jun 2026 |
| Deutsche Bank AG | 16.7M | 0.96% | +18.56% | Jun 2026 |
| Wells Fargo & Co | 15.2M | 0.88% | -4.60% | Jun 2026 |
| JPMorgan Chase & Co | 15.1M | 0.87% | -43.60% | Jun 2026 |
| State Farm Mutual Automobile Ins Co | 13.6M | 0.78% | 0.00% | Jun 2026 |
| FMR Inc | 13.4M | 0.78% | +23.77% | Jun 2026 |
Abbott Laboratories company profile
- Company name
- Abbott Laboratories
- Ticker
- ABT.US
- Exchange
- USA Stocks
- Listed since
- Jan 13, 1978
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 122,000
- Fiscal year end
- December
- Address
- 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400
- Phone
- 224 667 6100
- Website
- abbott.com
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Abbott Laboratories management
10- Mr. Robert B. FordExecutive Chairman & CEO · born 1974
- Mr. Philip P. BoudreauCFO & Executive VP of Finance · born 1973
- Mr. Daniel Gesua Sive SalvadoriExecutive VP and Group President of Established Pharmaceuticals & Nutritional Products · born 1979
- Mr. Christopher J. ScogginsExecutive Vice President of Diabetes Care · born 1970
- Ms. Lisa D. EarnhardtExecutive VP & Group President of Medical Devices · born 1970
- Ms. Sabina EwingSenior VP of Business & Technology Services and Chief Information Officer · born 1974
- Mr. Michael ComillaVice President of Investor Relations.
- Erica L. BattagliaVP and Chief Ethics & Compliance Officer
- Ms. Elizabeth C. CushmanExecutive VP, General Counsel & Secretary · born 1970
- Ms. Melissa BrotzSenior Vice President of Global Marketing & External Affairs